London, United Kingdom, November 19, 2026
GSK plc has announced that its investigational cancer medicine velzatinib has received Orphan Drug Designation (ODD) from Japan’s Ministry of Health, Labour and Welfare for the treatment of gastrointestinal stromal tumour (GIST). The designation represents an important regulatory milestone for the company’s oncology pipeline and supports the continued clinical development of velzatinib in a rare cancer with significant unmet medical needs. The decision was supported by findings from the ongoing Phase I/Ib StrateGIST 1 clinical trial, which demonstrated promising anti-tumour activity and a tolerability profile in patients with advanced GIST. The Japanese designation adds to the medicine’s existing regulatory recognitions, including U.S. Food and Drug Administration (FDA) Fast Track designation and orphan drug designations in the United States and European Union. GSK is also accelerating the development programme, with Phase III studies underway in both first-line and second-line advanced or metastatic GIST. The company reported that enrolment in the second-line study is progressing ahead of schedule, with data expected in the second half of 2027. The latest development strengthens GSK’s efforts to investigate targeted treatment approaches for patients whose disease is driven by KIT mutations and who may develop resistance to existing therapies.
Velzatinib Targets KIT Mutations in Gastrointestinal Stromal Tumours
Velzatinib is an investigational, highly selective KIT inhibitor specifically designed to target gastrointestinal stromal tumours. KIT is a receptor tyrosine kinase involved in cellular signalling, growth and survival. Mutations in the KIT gene are important drivers of GIST development and progression. According to GSK, approximately 80% of GIST cases are driven by KIT mutations, making this signalling pathway an important therapeutic target. Velzatinib has been designed to inhibit clinically relevant primary and key secondary KIT mutations, including mutations associated with resistance to previous treatment. This is particularly relevant because patients receiving first-line treatment can develop additional KIT mutations that contribute to disease progression and limit the effectiveness of available medicines. GSK reports that approximately 90% of patients treated in the first-line setting develop new KIT mutations. Existing tyrosine kinase inhibitors have improved outcomes for people with GIST, but resistance and tolerability challenges remain important limitations. By targeting a broad spectrum of clinically relevant KIT mutations, velzatinib is being investigated as a potential treatment option across different stages of advanced disease. However, its clinical benefit and safety will need to be established through the ongoing clinical development programme and regulatory review.
Phase III Studies Advance Across First-Line and Second-Line Treatment
GSK is progressing velzatinib through two Phase III clinical development programmes designed to evaluate its potential in different treatment settings. The first-line programme, known as StrateGIST Frontline, is investigating velzatinib compared with imatinib in adults with previously untreated metastatic or unresectable GIST. The second-line programme is evaluating velzatinib against sunitinib in patients whose disease has progressed following imatinib treatment. These studies are intended to establish the medicine’s efficacy and safety in clinically relevant patient populations. The second-line trial is progressing ahead of schedule in terms of enrolment, with results expected during the second half of 2027. In addition, GSK is conducting StrateGIST J, a Phase II study in Japan evaluating velzatinib in patients with metastatic or unresectable GIST whose disease has progressed or who cannot tolerate available treatment options. The company also plans to share seven velzatinib-related scientific abstracts at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting, held November 18–21 in Seoul, South Korea. The presentations include clinical analyses according to KIT mutation status, preclinical research examining mutation coverage and translational biomarker investigations. Together, these studies are expected to provide further evidence supporting the medicine’s development across treatment lines.
Orphan Designation Highlights Unmet Need in GIST
Gastrointestinal stromal tumour is a rare cancer that most commonly develops in the stomach or small intestine. Although treatment advances have improved outcomes over recent decades, advanced or metastatic disease remains challenging, particularly when tumours acquire resistance to available medicines. GSK estimates that approximately 80,000 to 120,000 people worldwide are diagnosed with GIST annually. Japan has one of the highest reported incidence rates, at approximately four cases per 100,000 people each year. Orphan Drug Designation is intended to encourage the development of medicines for rare diseases by providing regulatory incentives and development support. Receiving the designation does not mean that velzatinib has been approved for commercial use in Japan or that its effectiveness has been conclusively established. The medicine remains investigational, and its potential role in GIST will depend on the results of its clinical trials and subsequent regulatory decisions. For GSK, the Japanese designation adds to the regulatory momentum surrounding velzatinib and reinforces the company’s focus on targeted oncology medicines addressing treatment resistance and limited therapeutic options.
Source: GSK press release



